Robinson Chandler, CEO, reported a transaction classified as exercise at Monopar Therapeutics involving 9801.000000 shares. Reported holdings after the transaction were 109068.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
Chief Executive Officer
Represents shares acquired on vesting and settlement of restricted stock units.
Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
Represents shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.
On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU…
On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths…
On December 2, 2025, the reporting person was granted 49,133 restricted stock units, vesting 6/48ths (6,142) on June 30, 2026, and 3/48ths (3,071 shares) every 3 months thereafter until the RSU is ful…
0 other filings
0 recent txs